This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ANI Pharmaceuticals (ANIP) Q2 Earnings Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 11.63% and -2.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes ANI (ANIP) a New Buy Stock
by Zacks Equity Research
ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.
The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI
What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.
American Economy Hits the Gas: 5 Top Gainers
by Tirthankar Chakraborty
The U.S. economy grew 3.2% in the first quarter of 2019, primarily on two typically volatile components - inventories and trade.
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $69.66 in the latest trading session, marking a -0.49% move from the prior day.
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide
5 Stocks With Recent Price Strength to Enhance Your Returns
by Nalak Das
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.
Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA
by Zacks Equity Research
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
by Zacks Equity Research
QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ANIP) Outperforming Other Medical Stocks This Year?
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
by Zacks Equity Research
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.
5 Stocks With Increasing Cash Flows to Scoop Up Big Gains
by Moumita Chattopadhyay
Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
by Zacks Equity Research
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin
by Zacks Equity Research
Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
by Zacks Equity Research
FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.
Coherus (CHRS) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher
by Zacks Equity Research
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.